The National Science Foundation awarded Medchem Partners LLC a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) for the period of August 1, 2021 through July 31, 2022. The grant funds the development of novel inhaled nitric oxide therapy for pulmonary treatments related to COVID-19. The Engineering program seeks to improve quality of life and economic strength through engineering research and innovation. This award supports Medchem Partners' work advancing new inhaled nitric oxide therapies, which have potential applications for treating lung conditions exacerbated by COVID-19.
Generated 1/6/24, 11:16 AM